Literature DB >> 21404122

The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.

Nuggehally R Srinivas1.   

Abstract

The concept of prodrugs has been successfully executed for life cycle management options of several approved drugs and drugs in development. In addition to imparting ideal biopharmaceutical properties, such as solubility, permeability and lipophilicity, some prodrug concepts have also enabled site-specific drug delivery, prolonged the duration of therapeutic effect and improved therapeutic index. The strategic inclusion of prodrug concept during drug discovery and early development process brings in some unique challenges. The communication provides balanced perspectives on the rational use and challenges of prodrug concept during the drug discovery and development process.

Mesh:

Substances:

Year:  2011        PMID: 21404122     DOI: 10.1007/s13318-011-0035-z

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Prodrugs: Some thoughts and current issues.

Authors:  Valentino J Stella
Journal:  J Pharm Sci       Date:  2010-12       Impact factor: 3.534

2.  Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.

Authors:  Anette G Sams; Gitte K Mikkelsen; Mogens Larsen; Morten Langgård; Mark E Howells; Tenna J Schrøder; Lise T Brennum; Lars Torup; Erling B Jørgensen; Christoffer Bundgaard; Mads Kreilgård; Benny Bang-Andersen
Journal:  J Med Chem       Date:  2011-01-06       Impact factor: 7.446

3.  Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.

Authors:  Tao Zhou; Robert C Hider; Peter Jenner; Bruce Campbell; Christopher J Hobbs; Sarah Rose; Mark Jairaj; Kayhan A Tayarani-Binazir; Alexander Syme
Journal:  Eur J Med Chem       Date:  2010-06-02       Impact factor: 6.514

4.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

5.  Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.

Authors:  Peter J Ruane; Andrew D Luber; Mary Beth Wire; Yu Lou; Mark J Shelton; C Tracey Lancaster; Keith A Pappa
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

6.  Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.

Authors:  Jing Sun; Arik Dahan; Gordon L Amidon
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

7.  In vitro hydrolysis of RR,SS-threo-methylphenidate by blood esterases--differential and enantioselective interspecies variability.

Authors:  N R Srinivas; J W Hubbard; G McKay; E M Hawes; K K Midha
Journal:  Chirality       Date:  1991       Impact factor: 2.437

8.  Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity.

Authors:  Huw D Thomas; Kappusamy Saravanan; Lan-Zhen Wang; Mei-Ju Lin; Julian S Northen; Hannah Barlow; Marion Barton; David R Newell; Roger J Griffin; Bernard T Golding; Nicola J Curtin
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

9.  Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.

Authors:  Hao-Jie Zhu; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

10.  In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.

Authors:  Ronda Schaadt; Debora Sweeney; Dean Shinabarger; Gary Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

View more
  1 in total

1.  Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.

Authors:  Morten Rohde; Niels M Rk; Anders E Håkansson; Klaus G Jensen; Henrik Pedersen; Tina Dige; Erling B J Rgensen; René Holm
Journal:  Results Pharma Sci       Date:  2014-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.